NKNuri Kaydıhan

Nuri Kaydıhan

*This is an algorithmically generated author record based on publicly available information.

Nuri Kaydıhan has a total of 47 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Patterns of care in the use of radiotherapy for thymoma: a TROD thoracic oncology working group survey (TROD 08-013)

    by Nuri Kaydıhan, Esra Kaytan Sağlam, Fazilet Öner Dinçbaş

    We aimed to evaluate current practices among radiation oncologists in Turkey in the treatment of thymoma patients, including preferred staging systems, indications for adjuvant radiotherapy (RT), and RT dose schemes. We distributed a 19-item online questionnaire to 120 radiation oncologists affiliated with the TROD Thoracic Oncology Working Group. The survey covered demographics, clinical workflow, treatment indications, staging system preferences, guideline utilization, and RT dose regimens. Fifty-three physicians participated. Most had ≥ 10 years of experience (85%) and academic titles (60%). A thoracic oncology tumor board was operated in 60.4% of centers. The Masaoka staging system was preferred by 66%, while TNM was used by 28.3%. In stage II thymoma patients with R0 resection, 67.9% recommended adjuvant RT regardless of histological subtype if there was capsular proximity. In stage IIA, the indication for RT was especially frequent for B2-B3 histology (45.3%), and similarly in stage IIB (43.4%). For locally advanced but potentially resectable cases, 43.4% favored induction chemotherapy followed by surgery, and 28.3% performed postoperative RT. In potentially unresectable disease, neoadjuvant chemoradiotherapy (47.2%) and definitive chemoradiotherapy (35.8%) were common. Postoperative RT doses varied: R0 resections most often received 45-50 Gy (85%), rising to 50-54 Gy (79.2%) if capsular proximity was present. R1 resections more often received 50-54 Gy (41.5%) or 54-60 Gy (39.6%). R2 disease was usually treated with higher doses (54-70 Gy, most frequently 66-70 Gy at 37.7%). After induction chemotherapy, neoadjuvant RT most commonly used 45-50 Gy (67.9%), while definitive RT typically used 60-66 Gy (43.4%) or 66-70 Gy (39.6%). Multidisciplinary management aligned with international guidelines is common in thymoma treatment in Turkey. Capsular proximity and histological subtype are key determinants for adjuvant RT decisions. Postoperative RT doses were escalated according to residual tumor burden and resection status. In locally advanced or unresectable cases, neoadjuvant strategies are widely adopted.

  • Is radiotherapy still an option for residual retroperitoneal masses in stage IIC seminoma?

    by Halil Cumhur Yıldırım, Şahin Dikmen, Yeliz Gürsoy, Nuri Kaydıhan, Fazilet Öner Dinçbaş

    Purpose In patients with clinical stage IIC seminoma, residual retroperitoneal masses are detected in up to 80% of patients after chemotherapy. Lesions < 3 cm are generally monitored; however, the management of patients with residuals > 3 cm remains a matter of debate. Herein, we present a case series of these patients who underwent radiotherapy (RT) and discuss the role of RT in these cases. Methods Three patients with de novo and two patients with relapsed stage IIC seminoma who underwent RT for retroperitoneal residual masses after chemotherapy at two centers between 2014 and 2025 were retrospectively evaluated. All treatment decisions were made by a multidisciplinary board. Results The median age of the patients was 43 (26–47) years, and the median follow-up was 30 (10–120) months. Following radical orchiectomy, all patients received 3–4 cycles of BEP chemotherapy. The median size of the post-chemotherapy residual was 6.5 (3.2–8.5) cm. PET-CT was positive with SUVmax > 3 for all patients. Two patients received only paraaortic RT, three patients received paraaortic + ipsilateral pelvic lymph node RT with a total dose of 25.5 Gy. An additional dose of 10 Gy was prescribed to the residual mass. All treatments were implemented with intensity-modulated radiotherapy (IMRT). Three patients experienced grade 1 nausea. No recurrence or secondary malignancy was detected at final follow-up. Conclusion Radiotherapy may be considered as a potential non-invasive option for managing residual retroperitoneal masses after chemotherapy in stage IIC seminoma, particularly in patients with a high risk of recurrence and in whom retroperitoneal lymph node dissection (RPLND) is anticipated to be associated with morbidity.

  • Open Access

    Whole brain radiotherapy and simultaneous integrated boost: is it still a viable treatment for multiple brain metastases in the era of SRS?

    by Halil Cumhur Yıldırım, Nuri Kaydıhan, Ecem Demir, Deniz Azaklıoğlu, Fazilet Öner Dinçbaş

    Background: The objective of this study was to determine the outcomes of whole brain radiotherapy (WBRT) + simultaneous integrated boost (SIB) treatment in patients with multiple brain metastases. Materials and methods: 34 patients who were treated for multiple brain metastases with WBRT + SIB in two radiation oncology departments between 2014 and 2020 were evaluated retrospectively. Intracranial control and overall survival after radiotherapy (RT) were calculated with the Kaplan-Meier test. The prognostic factors of survival after RT were determined with Cox regression analysis. Results: The median age was 62 [interquartile range (IQR): 57–69] years. Median survival after cranial RT was 10 [95% confidence interval (CI): 7–13] months. One-year intracranial control probability after RT was 83%. Acute and late RT toxicity were observed in 2 patients. After 3 months of follow-up, 23 (68%) patients had complete/near complete response, 9 (26%) had partial response, and 2 (6%) had stable disease. In univariate analysis, the factors affecting survival after cranial RT were the presence of neurological symptoms (p = 0.003) and Karnofsky performance score (KPS, p = 0.001). The median survival of patients with and without neurological symptoms was 5 (95% CI: 4–6) months and 16 (95% CI: 5–27) months. Median survival of patients with KPS 60, 70, 80, and 90 were 1, 5, 10 and 13 months, respectively. In multivariate analysis, the only statistically significant prognostic factor was KPS [hazard ratio (HR): 0.94 95% CI: (0.89–0.99), p = 0.031]. Conclusions: WBRT + SIB is a well-tolerated technique with a promising 1-year intracranial control rate of 83% for patients with multiple brain metastases who were not amenable to surgery and/or SRS, particularly in good performance status (KPS > 70) and without neurologic impairments. Keywords: brain metastasis (BM) whole brain radiotherapy (WBRT) simultaneous integrated boost (SIB) intensity-modulated radiation therapy (IMRT)

  • The role of radiotherapy in intracranial hemangiopericytoma/solitary fibrous tumors

    by Nuri Kaydıhan, Gözde Yazıcı, Petek Erpolat, Serra Kamer, Burak Erdemci, Emine Canyılmaz, Beste Melek Atasoy, Dicle Aslan, Ela Delikgöz Soykut, Enis Özyar, et al.

    Objective Intracranial hemangiopericytomas (HPC) are rare tumors. Radiotherapy (RT) is frequently performed after surgery, depending on tumor size, location, and the type of resection. Moreover, RT is preferred as an effective treatment for local recurrence and metastasis. With this multicenter study, we aimed to investigate the effectiveness of postoperative RT in intracranial HPC patients using modern RT techniques. Materials and methods Patients aged 16 years and older who underwent RT for histologically confirmed intracranial HPC were evaluated retrospectively. Forty-four patients from 17 institutions were included. Demographic characteristics of the patients, pathological findings, and prognostic factors were documented. The Kaplan–Meier method was used for local control (LC), distant metastasis-free survival (DMFS), progression-free survival (PFS), and overall survival (OS). The interval for survival analyses was calculated according to the end date of RT. Univariate and multivariate analysis methods were used for factors associated with survival and recurrence. Results Median age was 42 years (16–71) and 70% of the patients were male. The most common initial symptoms were pain (47.7%) and vision problems (15.9%). A supratentorial location was observed in 79.5% of patients. The median maximum tumor dimension was 4.7 (1.6–14) cm. Gross total (GTR) and subtotal resection (STR) were performed in 43.2% and 47.7% of patients, respectively. Adjuvant RT commenced a median of 6 (2–16) weeks after surgery. Postoperative RT was administered using conventionally fractionated intensity-modulated radiotherapy (IMRT) or stereotactic radiosurgery (SRS). A total median dose of 60 (38–66) Gy in a median of 30 (19–33) fractions was used for patients treated with IMRT and a total median dose of 24 (12–25) Gy in a median of 3 (1–5) fractions was used for patients treated with SRS. Local recurrence occurred in 9 patients and locoregional recurrence in 2 patients at a median of 48 months (range 26–143 months) after RT. Reoperation and reirradiation were applied to 5 patients, reirradiation to 4 patients, and reoperation to 2 patients as salvage treatments. Reirradiation was administered at a median dose of 35 (13.5–54) Gy using a median of 5 (1–30) fractions. At a median follow-up of 63 (6–262) months, 5‑year LC was 68.7%, DMFS 87.2%, PFS 60.8%, and OS 95.7%. The presence of residual macroscopic tumor before RT was associated with lower LC (p = 0.01) and shorter PFS (p = 0.04). In the presence of residual tumor before RT, 5‑year LC decreased from 92.9% to 46.7%, while 5‑year PFS decreased from 81.1% to 43.5% compared to patients with GTR. The presence of postoperative tumor was associated with a lower LC rate in Cox regression analyzes (p = 0.02). The hazard ratio was 6.2 (1.2–30). However, the effect of residual disease before RT on OS was not statistically significant. Conclusion Adjuvant radiotherapy is performed in the majority of patients with HPC, especially in cases where GTR cannot be performed. In our study, postoperative macroscopic residual tumor was found to be the only factor affecting LC and PFS in patients undergoing adjuvant RT, but its effect on OS was not shown. This may be due to the effectiveness of reoperation and/or reirradiation in the presence of recurrence after RT.


  • Open Access

    Correction: Adverse risk factors for salvage radiotherapy outcomes after radical prostatectomy in prostate cancer patients

    by Halil Cumhur Yıldırım, Selvi Tabak Dinçer, Gökhan Yaprak, Nuri Kaydıhan, Ceren Barlas, Çakır Numanoğlu, Melike Pekyürek, Günay Can, Fazilet Öner Dinçbaş

  • Adverse risk factors for salvage radiotherapy outcomes after radical prostatectomy in prostate cancer patients

    by Halil Cumhur Yıldırım, Selvi Tabak Dinçer, Gökhan Yaprak, Nuri Kaydıhan, Ceren Barlas, Numan Çakıroğlu, Melike Pekyürek, Günay Can, Fazilet Öner Dinçbaş

    Purpose To investigate salvage treatment approaches and treatment outcomes in high-risk prostate cancer after radical prostatectomy (RP). Methods In this retrospective, multicenter study, 272 patients who underwent salvage radiotherapy (RT) ± androgen deprivation therapy (ADT) for recurrent prostate cancer after RP between 2007 and 2021 were analysed. Univariate analyses of time to biochemical and clinical relapse after salvage therapies were conducted using Kaplan–Meier plots and log-rank tests. Multivariate analyses were performed using a Cox proportional hazards model to determine the risk factors for disease relapse. Results Median age was 65 (48–82) years. All patients underwent salvage prostate bed RT. Pelvic lymphatic RT was performed in 66 patients (24.3%) and ADT was included in 158 (58.1%) patients. The median PSA value before RT was 0.35 ng/mL. The median follow-up time was 64 (12–180) months. 5-years bRFS, cRFS, and OS were 75.1%, 84.8%, and 94.9% respectively. In multivariate cox regression analysis; seminal vesicle invasion (HR 8.64, 95% CI 3.47–21.48, p < 0.001), pre-RT PSA higher than 0.14 ng/mL (HR 3.79, 95% CI 1.47–9.78, p = 0.006), and ≥ 2 positive pelvic lymph nodes (HR 2.50, 95% CI 1.11–5.62, p = 0.027) were found to be unfavorable prognostic factors for bRFS. Conclusion Salvage RT ± ADT provided 5-years biochemical disease control in 75.1% of patients. Seminal vesicle invasion, ≥ 2 positive pelvic nodes and delayed administration of salvage RT (PSA levels higher than 0.14 ng/mL) were found to be adverse risk factors for relapse. Such factors should be taken into account during the decision process on salvage treatment.

  • Stereotactic Radiotherapy for Adrenal Metastases: A Multi-Institutional Review of Patient Characteristics and Outcomes – Turkish Society for Radiation Oncology SBRT Group Study (Trod SBRT 10-004)

    by Aysenur Elmali, Berna Akkus Yildirim, Mustafa Cengiz, Sezin Yuce Sari, Huseyin C. Onal, Tanju Berber, Aysun Arslantas Erken, Teuta Zoto Mustafayev, Banu Atalar, Ilhami Unal, et al.

    Introduction: This study aimed to report the outcomes of stereotactic body radiotherapy (SBRT) for adrenal metastasis in a retrospective multi-institutional cohort. Methods: The outcomes of 124 patients with 146 adrenal metastases who underwent SBRT within 11 years (2008–2019) were retrospectively evaluated. Survival outcomes were analyzed by the Kaplan-Meier method. Patient, tumor, and treatment characteristics and their effects on survival, local control (LC), and toxicity outcomes were analyzed by log-rank and multivariate Cox regression methods. Results: The median age was 60 years. The most frequent primary tumor site was the lung, followed by the gastrointestinal system and breast. The adrenal gland was the only metastatic site in 49 (40%) patients. Median biologically effective dose (BED)10 was 61 Gy. The overall LC rate was 83%, and it was positively correlated with the BED10 and fraction dose. The 1- and 2-year local recurrence-free survival, overall survival (OS), and progression-free survival (PFS) rate was 79% and 69%, 83% and 60%, and 31% and 12%, respectively. OS significantly improved with non-lung cancer and 65 Gy, and an isolated adrenal metastasis. Fourteen patients reported an acute toxicity, and late toxicity was observed in 3 patients, including one grade 5. Conclusion: A satisfactory LC rate was achieved for adrenal metastasis via SBRT. A higher BED10 and fraction dose were positive prognostic factors for tumor control. However, the main problem is DM in these patients, and systemic treatment options are needed to be improved.


  • Temporary Implant Irradiation: Survey of Turkish Society of Radiation Oncology Breast Cancer Study Group

    by Nuri Kaydıhan, Gül Alço, Mustafa Şükrü Şenocak, Nuran Beşe

    Objective: To understand the clinical approach of radiation oncologists during the treatment of patients with breast reconstruction. Materials and Methods: A questionnaire survey was emailed to 105 active members of the Turkish Radiation Oncology Society, the Breast Cancer Study Group. The factors associated with radiation oncologists and their current practice was identified. Results: Fifty radiation oncologists (47.6%) responded, and most of the responders (83%) were physicians who treated >50 new breast cancer patients annually. The majority of the physicians worked in academic hospitals and had more than 15 years of work experience. The early reconstruction rate was noted to be low among patients with mastectomy (<10% of the mastectomy patients) (p<0.05). Early implant irradiation with temporary tissue expander was noted to be a more common procedure. The majority of the respondents (68%) preferred to irradiate an inflated implant (20% total, 80% partial). In addition, 22% of the physicians declared that they routinely used bolus and that 60% of them used it only for patients at a high risk of local recurrence factors. Conclusion: It can thus be concluded that variations exist between experienced radiation oncologists and others. Hypofractionation is not yet commonly practiced for patients with reconstruction in Turkey. A concrete consensus can be helpful to create a homogeneity in treatment decisions and practical applications.

  • Comparison of changes in renal function with dosimetric parameters in gastric cancer patients treated with adjuvant chemoradiotherapy

    by Nuri Kaydıhan, Kimia Çepni, Şefika Arzu Ergen, Mustafa Şükrü Şenocak, Didem Çolpan Öksüz

    Our objective was to analyze kidney damage using glomerular filtration rate (GFR) and dynamic renal scintigraphy (DRS) compared with dose volume histogram (DVH) parameters in gastric cancer patients.